Vericiguat

维立西呱

Report date: 2026/03/10 20:00:16
NME

Base Information

Drug NameVericiguat
Drug Alias NameVericiguatum维利昔夸威利西呱维利西呱Verquvo +[9
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSoluble guanylate cyclase stimulants
TargetsSoluble guanylate cyclase
Therapy Area/IndicationsCognition DisordersFatigueObesity +[14
Global Approved IndicationsHeart FailureCardiovascular Diseases
Approved Indications in ChinaHeart Failure
Original Approved Country/TerritoryUnited States
Original Approved Date2021/01/19
Country/TerritoryCzechiaBelgiumBulgaria +[50
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active IndicationsCognition DisordersFatigueObesity +[12
Inactive IndicationsCoronary Artery DiseaseCardiovascular Diseases

Other Information

ATC CodeC01DX22